CDIX (Cardiff Lexington) 10-Year Sharpe Ratio: N/A (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIX Cardiff Lexington Corp CDIX
21 GF Score
Price $0.12
GF Value $0.37
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cardiff Lexington 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-05), Cardiff Lexington's 10-Year Sharpe Ratio is Not available.

Cardiff Lexington  (OTCPK:CDIX) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Cardiff Lexington 10-Year Sharpe Ratio Related Terms

CDIX vs NIVF, RHEP, XCRT: 10-Year Sharpe Ratio Comparison

For the Medical Care Facilities subindustry, Cardiff Lexington's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Lexington 10-Year Sharpe Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Lexington's 10-Year Sharpe Ratio falls into.


CDIX
21GF Score
Cardiff Lexington Corp CDIX
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Lexington 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Is Cardiff Lexington (CDIX) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Lexington stock appears to be undervalued. The current stock price of $0.12 is trading 68.6% below its estimated GF Value™ of $0.37. GuruFocus considers Cardiff Lexington to be Possible Value Trap.

Key valuation signals for CDIX:

  • 10-Year Sharpe Ratio: N/A
  • GF Value™: $0.37 vs. price of $0.12 (68.6% below fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Lexington Business Description

Address 710 East Main Street, Lexington, KY, USA, 40502
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
21GF Score

Get the complete analysis for CDIX

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.37
GF Value